Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Metformin May Delay Aging and Cancer Progression

Metformin delays aging and cancer progression by reducing the production of....
Advertisement

A research team from the University of Montreal revealed the mechanism of how metformin slows aging and cancer progression. In a study, they found that metformin reduces the production of inflammatory cytokines. These inflammatory cytokines are key players activating the immune system in tissue damage during aging and tumor growth in cancer development.

Dr. Gerardo Ferbeyre and colleagues found that metformin decreases cytokines by disrupting a protein called NF-kB that would normally trigger cytokine activation and the immune system. When cytokines are overproduced, this leads to pathological inflammation that is involved in both the aging and cancer processes.

Dr. Ferbeyre said, "This is an important finding with implications for our understanding on how the normal organism defends itself from the threat of cancer and how a very common and safe drug may aid in treatment of some cancers and perhaps slow down the aging process." He added, "It remains that determining the specific targets of metformin would give us an even better opportunity of profit from its beneficial effects. That's what we want to figure out next." This finding may be an important step in finding a place for metformin therapy in anti-cancer and anti-aging therapy.

"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-B activation" Aging Cell, March 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 April, 2013 and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Past five issues: Issue 788 | Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Important Advances in Type 1 Diabetes Research
Posted June 25, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Second Tuberculosis Vaccine Treatment for Type 1 Diabetes Underway
Posted June 19, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Are you seeing more diabetic patients due to the Affordable Care Act?

CME/CE of the Week
Jeffrey Mechanick

Category: General Diabetes
Credits: .75